Morphic Therapeutic

Developer of small molecule integrin inhibitors for immunological, fibrotic, neoplastic and vascular diseases

placeWaltham, Massachusetts, United States calendar_todayFounded 2015 groups121 employees language morphictx.com

Registered entities

Innovation

23 patent families (8 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace accelerating. Cited 3,557 times.

YearFilings
20182
20193
20207
20219
20228
20237
202410
202518
202612

Investor mix

11 investors on record; lead investors include SR One, Pfizer Venture Investments, Omega Funds, Novo Holdings; 1 has since exited.

Investor typeCountShare
Venture capital655%
Accelerator & incubator19%
Other / undisclosed436%
Coming soon